mva rh5
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02181088)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Plasmodium falciparumImmunity, active
Plasmodium falciparum immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva rh5
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03435874 | Phase 1 | Apr 12, 2018 | Ifakara Health Institute, Medical Research Council, University of Oxford |
| NCT02181088 | Phase 1 | Aug 1, 2014 | European Commission, University of Oxford |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 2 | 2 | 1 | 2014 |
| European Commission | Government | 1 | 0 | 1 | 2014 |
| Ifakara Health Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Medical Research Council | Government | 1 | 0 | 1 | 2018 |
4 organizations
Page 1 / 1